top of page

​

  •  Artificial Intelligence in multitargeting approaches in chronic recalcitrant diseases

  • Therapy areas: Respiratory, Dermatology, Inflammation, Cardio-Metabolic, Chronic Pain and Oncology

  • Indications: Broad (Block buster approach), targeted (personalized treatment approach), orphan, niche

  • Disease Biology: Extensive background of novel targets, chronic disease mechanisms, cellular / biochemical / immune / genomic / proteomic disease signatures, disease heterogeneity and endotypes, biomarkers for patient stratification, treatment algorithms, unmet medical needs, global pipeline molecules and competitive positioning 

  •  New Drug Discovery Research

    • ​Therapeutic targets: First in class vs Best in class, Kinases, GPCRs, Enzymes / Ion Channels / Transcription Factors and others

    • Route of administration: Oral, inhaled, topical on skin

    • Preclinical research strategy: road map / milestones / GO-NO GO decision gates

    • Preclinical development: Target to IND lead nomination

    • Preclinical, translational and early human POC study designs

    • NCE out-licensing: Preclinical data package, confidential presentations, due diligence meetings

    • Extensive experience in research collaborations with world-class Research Institutes, Universities and CROs. A broad  network of international scientific experts for external advice

    • Establishment of Discovery Biology Lab​​

  • ​ Branded specialty drug products: ​​​

    • McAb-drug conjugates

    • Scientific evaluation and guidance on global in-licensing opportunities to Global Business Development and Portfolio team

    • ​Ideation of novel, differentiated molecule for quick market entry - single agent or fixed dose combination

  • Health & Wellness:

    • ​Microbiome based and other Consumer Products, Nutraceuticals

bottom of page